Which of the following is listed as a part of a REMS program?

• A. MedGuides
• B. Post-market surveillance
• C. Quarterly financial report
• D. Pharmacoeconomic analysis

Answer: (A)

REMS programs are safety-focused efforts required by the FDA for certain medicines with significant risks, aimed at ensuring that benefits outweigh harms through risk communication and safeguards. A common element you’ll encounter is a Medication Guide (MedGuide), a patient-facing document that explains the drug’s major risks, proper usage, and what to watch for. It’s designed to help patients understand how to take the medication safely and to empower informed decision-making, which is exactly what REMS programs strive to achieve for high-risk drugs.

The other options don’t fit as standard REMS components. Post-market surveillance is a broader ongoing safety activity that can occur alongside REMS but isn’t itself a defined element that REMS programs must list. Quarterly financial reports and pharmacoeconomic analyses relate to business or economic considerations, not to patient safety risk mitigation. So MedGuides are the element that is listed as part of a REMS program.